天津医药 ›› 2016, Vol. 44 ›› Issue (4): 441-443.doi: 10.11958/20150121

• 实验研究 • 上一篇    下一篇

长春西汀对糖尿病大鼠静脉桥移植术后再狭窄的影响

张觉宇, 蓝志纯, 霍天明, 李世康△   

  1. 广西医科大学第一附属医院心胸外科 (邮编530021)
  • 收稿日期:2015-08-26 修回日期:2015-10-13 出版日期:2016-04-15 发布日期:2016-05-20
  • 通讯作者: △通讯作者 E-mail: gxtinghaodi@163.com E-mail:gxtinghaodi@163.com
  • 作者简介:张觉宇 (1990), 男, 硕士在读, 主要从事冠状动脉搭桥术研究
  • 基金资助:
    广西科学研究与技术开放计划项目 (桂科攻1355005-4-8)

Study on the effect of vinpocetine on the restenosis of venous bypass grafts in diabetic rats

ZHANG Jueyu, LAN Zhichun, HUO Tianming, LI Shikang△   

  1. Department of Thoracic and Cardiovascular Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
  • Received:2015-08-26 Revised:2015-10-13 Published:2016-04-15 Online:2016-05-20
  • Contact: △Corresponding Author E-mail: gxtinghaodi@163.com E-mail:gxtinghaodi@163.com

摘要: 摘要: 目的 探讨长春西汀 (Vinp) 对糖尿病静脉桥移植术后再狭窄的影响及可能作用机制。方法 36只SD大鼠随机分为对照组和Vinp组, 通过建立糖尿病模型进行自体颈外静脉-颈总动脉移植, 分别以生理盐水或者Vinp进行腹腔注射, 于术后0周、 2周及4周取移植静脉桥制作病理切片, 测量内膜厚度, 免疫组化法检测增殖细胞核抗原 (PCNA)蛋白表达, 通过细胞增殖指数定量描述。Western blot 检测核转录因子 (NF) -κB的磷酸化水平。结果 Vinp干预后明显减少糖尿病血管桥内膜增厚[术后2周:(17.06±5.10) μm vs.(39.79±7.84) μm, P < 0.01; 4周:(30.94±5.18) μm vs.(63.67± 18.09) μm, P < 0.01], 同时还降低糖尿病静脉桥PCNA蛋白的表达[术后2周:(21.07±1.38) %vs.(28.13±1.35) %, P < 0.01; 4周:(31.73±1.38) %vs.(63.67±18.09) %, P < 0.01], 并抑制NF-κB的磷酸化 (术后2周: 1.08±0.42 vs. 0.84±0.12, P < 0.01)。结论 Vinp 能有效抑制糖尿病静脉桥术后内膜增厚, 其机制可能与抑制NF-κB 通路, 从而抑制炎症反应有关。

关键词: 糖尿病, 实验性, 移植物闭塞, 血管, 增殖细胞核抗原, NF-κB, 长春西汀, 静脉桥, 再狭窄

Abstract: Abstract: Objective To expose the effect and its potential mechanism of vinpocetine (Vinp) on the restenosis of dia⁃ betic grafted veins. Methods Thirty-six Sprague-Dawley rats were randomized into saline control group and Vinp treat⁃ ment group. The autologous jugular vein to carotid artery transplantation was performed in diabetic model rats. Normal sa⁃ line or Vinp were intraperitoneally injected. The rats were sacrificed at 0, 2 or 4 weeks after surgery, then the grafted veins were harvested. The pathological sections were used to detect the effect of Vinp on intimal hyperplasia. The protein expres⁃ sion of proliferating cell nuclear antigen (PCNA) was detected by immunohistochemical method, and which was described by cell proliferation index. The phosphorylation of NF-κB was detected by Western blot assay. Results The treatment of Vinp on intimal hyperplasia in vivo was significant at two weeks after surgery (17.06±5.10) μm versus control group (39.79±7.84 μm, P < 0.01), (30.94±5.18) μm versus (63.67±18.09) μm at four weeks after surgery (P < 0.01). Vinp treatment effectively reduced the protein expression of PCNA [2 weeks: (21.07±1.38)% vs. (28.13±1.35)%, P < 0.01; 4 weeks: (31.73±1.38)% vs. (63.67±18.09)%, P < 0.01]. The treatment of Vinp inhibited phosphorylation of NF-κB at two weeks (1.08±0.42 vs. 0.84± 0.12, P < 0.01). Conclusion Vinpocetine can effectively attenuate intimal hyperplasia in diabetic grafted veins, which might be related to its effect on inhibiting phosphorylation of NF-κB as well as inflammation.

Key words: diabetes mellitus, experimental, graft occlusion, vascular, proliferating cell nuclear antigen, NF-kappa B, Vinpocetine, vein graft, restenosis